Arcutis has achieved a pivotal profitability inflection, with Q2 2026 revenue surging 59.3% year-over-year to $129.9M and operating income turning positive at $16.4M, driven by ZORYVE's commercial traction and a 91.6% gross margin. However, the balance sheet r...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.11+99.7% vs $0.06 | $130M+9.3% vs $119M |
Q2 2026 May 6, 2026 | -$0.09-350.0% vs -$0.02 | $105M+1.7% vs $104M |
Q1 2026 Feb 25, 2026 | $0.13+333.3% vs $0.03 | $130M+14.5% vs $113M |
Q4 2025 Oct 28, 2025 | $0.06+160.0% vs -$0.10 | $99M-10.4% vs $111M |
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs) of Arcutis common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026, in New York.
Benchmark ARQT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Arcutis Biotherapeutics, Inc. (ARQT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.38 | $3.3B | -202.92 | 91.34% | -4.29% | -9.3% | — | |
| $6.50 | $178.89M | -13.83 | 10.2% | -8.95% | -20.23% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — |
Arcutis Biotherapeutics, Inc. (ARQT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Arcutis Biotherapeutics, Inc. (ARQT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 16, 2026·SEC
Jun 9, 2026·SEC
Get notified when ARQT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arcutis Biotherapeutics, Inc. (ARQT) stock FAQ — growth, dividends, profitability & financials explained
Arcutis Biotherapeutics, Inc. (ARQT) reported $464.0M in revenue for fiscal year 2025.
Arcutis Biotherapeutics, Inc. (ARQT) grew revenue by 91.3% over the past year. This is strong growth.
Yes, Arcutis Biotherapeutics, Inc. (ARQT) is profitable, generating $28.5M in net income for fiscal year 2025 (-4.3% net margin).
Arcutis Biotherapeutics, Inc. (ARQT) has a return on equity (ROE) of -9.3%. Negative ROE indicates the company is unprofitable.
Arcutis Biotherapeutics, Inc. (ARQT) generated $39.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
